Remove 2021 Remove Chemotherapy Remove Immunization
article thumbnail

AstraZeneca to acquire TeneoTwo and its blood-cancer therapeutic

European Pharmaceutical Review

By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response. “By The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

article thumbnail

Immunocore claims first-ever FDA approval for TCR cancer therapy

pharmaphorum

At the moment the only other BiTE to reach the US market is Amgen’s CD19-targeting Blincyto (blinatumomab), which has been approved for various types of leukaemia and made $340 million in sales in the first nine months of 2021.

FDA 124
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Transforming oncology with antibody therapeutics

European Pharmaceutical Review

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. Cancer Ther. 2020; 19(10): 2044–56.

article thumbnail

What side effects to expect from the shingles vaccine

The Checkup by Singlecare

The Shingrix vaccine triggers the immune system to respond to the varicella virus and suppress the outbreak of shingles,” says David Cutler , MD, a family medicine physician at Providence Saint John’s Health Center in Santa Monica, California. This is a typical immunization response as your body builds a defense against possible infection.

Vaccines 105
article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

Granzyme B is an enzyme released by activated immune cells and using this as a in vivo imaging biomarker has great potential to monitor immune cell activation in a variety of inflammatory diseases, autoimmune diseases, cancer and infections. What do you envision the future of radiopharmaceuticals to be like?

article thumbnail

Merck’s Keytruda flunks another prostate cancer test

pharmaphorum

The cancer is particularly challenging for immunotherapy, as it tends to have fewer mutations than other cancers, presenting fewer targets for immune cells, and tends to be immunologically ‘cold’, with few immune cells infiltrating the tumour. It remains ongoing with updated results due in the coming months.

article thumbnail

There is a large pipeline of CAR-T cell therapies for diffuse large B-cell lymphoma

Pharmaceutical Technology

Adoptive cell therapy (ACT) is a form of cancer treatment that involves the transfer of immune cells into a patient to help fight the disease, by eliminating cancer cells. billion in 2021 and is forecast to reach $2.4 According to GlobalData’s Epidemiology database, there were 5,446 incident cases of DLBCL in the UK in 2021.